PDCD1 and non-small cell lung carcinoma: In humans, the survival benefit and acceptable safety of concurrent anti-PD-1 therapy with chemotherapy or chemoradiation over monotherapies have been observed in advanced human cancers such as biliary tract [133] or NSCLC [134,135,136].